Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2150 of 2873 entries
View as:

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Phase: N/A Priority: Normal
NCT ID: NCT05010772 Org: User:
Start: 10/25/21 End: 12/31/26 Due: 12/31/27

Determinants of Multiple Health Risk Behaviors Among Latinos

Phase: N/A Priority: Normal
NCT ID: NCT01479257 Org: User:
Start: 01/31/12 End: 01/31/23 Due: 01/31/24

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Phase: N/A Priority: Normal
NCT ID: NCT00390793 Org: User:
Start: 09/28/06 End: 02/02/24 Due: 02/02/25

Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study

Phase: N/A Priority: Normal
NCT ID: NCT05763771 Org: User:
Start: 02/15/24 End: 12/01/27 Due: 12/01/28

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04771520 Org: User:
Start: 01/20/21 End: 12/31/26 Due: 12/31/27

Morphine Versus Methadone As First Line Strong Opioid for Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT00634010 Org: User:
Start: 02/29/08 End: 01/31/15 Due: 01/31/16

Sleep and Physical Activity Intervention for Increasing Physical Activity in Overweight or Obese and Sedentary African Americans

Phase: N/A Priority: Normal
NCT ID: NCT04236882 Org: User:
Start: 10/04/19 End: 04/30/30 Due: 04/30/31

Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia

Phase: N/A Priority: Normal
NCT ID: NCT02292368 Org: User:
Start: 11/10/14 End: 08/30/22 Due: 08/30/23

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00877773 Org: User:
Start: 04/30/09 End: 06/30/14 Due: 06/30/15

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

Phase: N/A Priority: Normal
NCT ID: NCT06708949 Org: User:
Start: 03/20/25 End: 12/15/28 Due: 12/15/29

Depression and Adherence in Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00498875 Org: User:
Start: 03/15/05 End: 12/31/26 Due: 12/31/27

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04810091 Org: User:
Start: 05/18/21 End: 08/26/25 Due: 08/26/26

The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04875728 Org: User:
Start: 09/08/20 End: 02/02/27 Due: 02/02/28

Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury

Phase: N/A Priority: Normal
NCT ID: NCT02882373 Org: User:
Start: 10/23/18 End: 05/15/19 Due: 05/15/20

Association Between Gut Microbiome and Dietary Determinants and Vaccine Response

Phase: N/A Priority: Normal
NCT ID: NCT05239403 Org: User:
Start: 08/24/21 End: 02/28/25 Due: 02/28/26

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02710253 Org: User:
Start: 05/25/16 End: 05/30/26 Due: 05/30/27

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00473551 Org: User:
Start: 05/31/07 End: 11/30/09 Due: 11/30/10

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Phase: N/A Priority: Normal
NCT ID: NCT00941499 Org: User:
Start: 07/31/09 End: 05/31/14 Due: 05/31/15

Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02940223 Org: User:
Start: 03/16/17 End: 11/24/20 Due: 11/24/21

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Phase: N/A Priority: Normal
NCT ID: NCT00102648 Org: User:
Start: 12/21/04 End: 12/01/25 Due: 12/01/26

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Phase: N/A Priority: Normal
NCT ID: NCT00890656 Org: User:
Start: 06/30/03 End: 01/31/11 Due: 01/31/12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Phase: N/A Priority: Normal
NCT ID: NCT06683755 Org: User:
Start: 05/01/25 End: 08/16/32 Due: 08/16/33

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04310397 Org: User:
Start: 01/29/20 End: 10/09/23 Due: 10/09/24

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02918474 Org: User:
Start: 04/28/17 End: 09/30/26 Due: 09/30/27

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06085638 Org: User:
Start: 09/14/23 End: 10/20/23 Due: 10/20/24